ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "B-Cell Targets"

  • Abstract Number: 1905 • ACR Convergence 2021

    CD11c+ Expression Associates with IFN-λ Responsiveness in Human B Cells with Clinical Implications for SLE

    Jennifer Barnas1, Jennifer Barnard2, Cameron Baker2, Nida Meednu2, Andrew McDavid1, R. John Looney1 and Jennifer Anolik2, 1University of Rochester, Rochester, NY, 2University of Rochester Medical Center, Rochester, NY

    Background/Purpose: Type I interferon (IFN), namely IFN- α, and B cell aberrations are long recognized in systemic lupus erythematosus (SLE) pathogenesis. Type I IFN receptor…
  • Abstract Number: 0004 • ACR Convergence 2021

    Unappreciated Systemic Metabolic Functions of the Canonical B Cell Cytokines, BAFF and APRIL: Regulation of Lipolysis and Non-shivering Thermogenesis and Protection from Obesogenic Diet Induced Weight Gain

    Isaac Harley1, Calvin Chan2, Paul Pfluger3, Trompette Aurelien4, Traci Stankiewicz5, Jessica Allen5, Maria Moreno-Fernandez5, Michelle Damen5, Jarren Oates5, Pablo Alarcon5, Jessica Doll6, Matthew Flick7, Leah Flick8, Juan Sanchez-Gurmaches9, Rajib Mukherjee9, Rebekah Karns10, Michael Helmrath11, Thomas Inge12, Stuart Weisberg13, Sunje Pamp14, David Relman15, Randy Seeley16, Matthias Tschoep17, Chris Karp18 and Senad Divanovic8, 1University of Colorado Anschutz Medical Campus, Aurora, CO, 2University of Cincinnati, Cincinnati, OH, 3Technical University of Munich, Munich, Germany, 4Le Centre hospitalier universitaire vaudois, Lausanne, Switzerland, 5Cincinnati Children's Hospital Medical Center, Division of Immunobiology, Cincinnati, OH, 6Cincinnati Children's Hospital Medical Center, Division of Immunobiology, Cincinn, OH, 7Division of Experimental Hematology, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, 8Division of Immunobiology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 9Division of Endocrinology, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, 10Division of Gastroenterology, Hepatology and Nutrition, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, 11Pediatric General and Thoracic Surgery, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, 12Department of Surgery, Children’s Hospital Colorado, Aurora, CO, 13Columbia University Medical Center, New York, NY, USA, New York, NY, 14Danmarks Tekniske Universitet, Lyngby, Denmark, 15Department: Medicine - Med/Infectious Diseases - Stanford University, Stanford, 16Department of Surgery, Internal Medicine and Nutritional Sciences, University of Michigan, Ann Arbor, MI, 17Division of Metabolic Diseases, Technische Universität München, Munich, Germany, 18Division of Molecular Immunology, Cincinnati Children’s Hospital Medical Center, Cincinnati

    Background/Purpose: The impact of immune mediators on weight homeostasis and systemic metabolism remains underdefined. Interrogation of resistance to diet-induced obesity in mice lacking a negative…
  • Abstract Number: 0775 • ACR Convergence 2020

    T and B Cell Responses to Common Tenascin-C Peptides in RA

    JING Song1, Anja Schwenzer2, Sara Turcinov3, Alicia Wong2, Cliff Rims1, Lorena Rodriguez Martinez2, David Arribas-Layton4, Christina Gerstner5, Virginia Muir6, Jeffrey Carlin7, Kim Midwood2, Vivianne Malmström8, Eddie James1 and Jane Buckner1, 1Center for Translational Immunology, Benaroya Research Institute at Virginia Mason, Seattle, WA, 2Kennedy Institute of Rheumatology, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom, 3Division of Rheumatology, Department of Medicine,Center for Molecular Medicine, Institutet, Stockholm, Sweden, 4Center for Translational Immunology, Benaroya Research Institute at Virginia Mason, Seattle, 5Division of Rheumatology, Department of Medicine,Center for Molecular Medicine, Karolinska Institutet, Stockholm, Sweden, 6Center for Systems Immunology, Benaroya Research Institute at Virginia Mason, Seattle, WA, 7Department of Rheumatology, Virginia Mason Medical Center, Seattle, WA, 8Karolinska Institutet, Stockholm, Stockholms Lan, Sweden

    Background/Purpose: Although autoreactive CD4+ T cell and antibody responses against citrullinated antigens are known to contribute to loss of immune tolerance in rheumatoid arthritis (RA),…
  • Abstract Number: 0860 • ACR Convergence 2020

    PREVAIL 1: A Multiple Ascending Dose Study in Normal Healthy Volunteers of PRV-3279, a Novel Bispecific DART Molecule Targeting CD32B and CD79B on B Cells, with Potential for Treatment of SLE

    Paul Dunford1, Gail Comer1, Ralph Raymond1, Donald Jung1, Paul Moore2, Francisco Leon1 and Joan Merrill3, 1Provention Bio, Oldwick, NJ, 2MacroGenics, Rockville, MD, 3Oklahoma Medical Research Foundation, Oklahoma City, OK

    Background/Purpose: B-cell targeted therapeutics have proven efficacious in the treatment of autoimmune disorders.  A desired improvement in efficacy and safety necessitate the development of alternate,…
  • Abstract Number: 0947 • ACR Convergence 2020

    STING Gain-of-Function in Radio-resistant Cells Supports a Lymphocyte Dependent Auto-inflammatory Lung Disease

    Kevin Gao1, Mona Motwani1, Ann Marshak-Rothstein2 and Katherine Fitzgerald1, 1University of Massachusetts medical school, worcester, MA, 2University of Massachusetts medical school, Newton, MA

    Background/Purpose: cGAS-STING is a cytosolic dsDNA sensing pathway whose regulation is vital to immune homeostasis. Pediatric patients with constitutively active STING mutations develop an autoinflammatory…
  • Abstract Number: 0991 • ACR Convergence 2020

    Pathogenic, Glycolytic PD-1+ B Cells Accumulate in the Hypoxic RA Joint

    Achilleas Floudas1, Nuno Neto2, Viviana Marzaioli3, Kieran Murray4, Barry Moran5, Michael Monaghan6, Candice Low7, Ronan Mullan8, Navin Rao9, Vinod Krishna9, Sunil Nagpal10, Douglas Veale11 and Ursula Fearon3, 1Molecular Rheumatology Trinity Biomedical Sciences Institute, Dublin, Dublin, Ireland, 2Department of Mechanical and Manufacturing Engineering, Dublin, Dublin, Ireland, 3Molecular Rheumatology, Trinity College Dublin, Dublin, Dublin, Ireland, 4Saint Vincent's University Hospital, Dublin 4, Dublin, Ireland, 5Trinity Biomedical Sciences Institute, Dublin, Ireland, 6Department of Mechanical and Manufacturing Engineering, Dublin, Ireland, 7EULAR Centre for Arthritis and Rheumatic diseases, St Vincents University Hospital, UCD, Dublin, Ireland, 8Adelaide and Meath Hospital, Dublin, Dublin, Ireland, 9Janssen R&D, Spring House, PA, 10Janssen Research & Development, Collegeville, PA, 11EULAR Centre for Arthritis and Rheumatic Diseases, St Vincents University Hospital, UCD, Dublin, Dublin, Ireland

    Background/Purpose: Rheumatoid arthritis (RA) often has a progressive and debilitating course, with significant impact on the patient’s quality of life. Despite the long-known association with…
  • Abstract Number: 0992 • ACR Convergence 2020

    Impact of Selective Inhibitors of Nuclear Export on SLE Plasma Cells Is Modulated by the BM Microenvironment

    Neha Nandedkar-Kulkarni1, Nida Meednu2, Jennifer Albrecht2, Jennifer Barnas2, Douglas Widman3 and Jennifer Anolik2, 1University of Rochester, Rochester, NY, 2University of Rochester Medical center, Rochester, NY, 3Karyopharm Therapeutics, Newton, MA

    Background/Purpose: Systemic lupus erythematous (SLE) is a complex autoimmune disorder with heterogeneous disease presentation and a multi-pronged pathogenesis. Although autoreactive plasma cells play a key…
  • Abstract Number: 0994 • ACR Convergence 2020

    Does Tofacitinib Impact B Cell Functions?

    Guillaume Decarriere1, Julie Mielle2, Bernard Combe3, Jacques Morel1, Rachel Audo2 and Claire Daien1, 1Rheumatology department, CHU Montpellier and University of Montpellier, Montpellier, France, 2Institut de génétique moléculaire de Montpellier (IGMM), Montpellier, France, 3University of Montpellier, Montpellier, France

    Background/Purpose: Tofacitinib (tofa) inhibits cytokine signaling mediated by JAK1 JAK3 pathways leading therefore to a decrease in Th17 and an increase of Treg cells. The…
  • Abstract Number: 0995 • ACR Convergence 2020

    Jo-1-Binding B Cells Undergo Limited Class-Switching but Are Biased Towards Autoreactive-Prone and Memory B Cell Subsets in Anti-histidyl-tRNA Synthetase Syndrome

    Jennifer Young-Glazer1, Alberto Cisneros2, Erin Wilfong1, Scott Smith1, Leslie J. Crofford1 and Rachel Bonami1, 1Vanderbilt University Medical Center, Nashville, TN, 2Vanderbit University Medical Center, Nashville, TN

    Background/Purpose: Idiopathic inflammatory myopathies (IIM) are systemic autoimmune diseases traditionally classified as dermatomyositis or polymyositis, but these disorders are increasingly defined by the presence of…
  • Abstract Number: 0997 • ACR Convergence 2020

    Novel Shared Antibody Specificities in Ro Antibody Negative Sjögren’s Syndrome

    Sherri Longobardi1, Constantin Georgescu2, Christina Lawrence3, Charmaine Moya3, Jonathan Wren4, Judith James5, Kathy Sivils3 and A. Darise Farris6, 1Graduate Program in Biological Sciences, University of Oklahoma Health Sciences Center; Arthritis and Clinical Immunology Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, 2Genes & Human Disease Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, 3Arthritis and Clinical Immunology Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, 4Genes & Human Disease Program, Oklahoma Medical Research Foundation, Oklahoma City, 5Oklahoma Medical Research Foundation, Oklahoma City, 6Arthritis and Clinical Immunology Program, Oklahoma Medical Research Foundation, Oklahoma City

    Background/Purpose: Sjögren’s syndrome (SS) is a rheumatic autoimmune disease characterized by focal lymphocytic infiltrates in the lacrimal and salivary glands, severe dry mouth and eyes,…
  • Abstract Number: 1050 • ACR Convergence 2020

    Rituximab in the Treatment of Interstitial Lung Disease Associated with Autoimmune Diseases: Experience from a Single Referral Center

    Belén Atienza-Mateo1, Sara Remuzgo-Martínez2, Diana Prieto-Peña1, Víctor Manuel Mora Cuesta3, David Iturbe-Fernández3, Sonia Fernández Rozas1, Alfonso Corrales1, José Manuel Cifrián2 and Miguel Ángel González-Gay4, 1Research group on genetic epidemiology and atherosclerosis in systemic diseases and in metabolic bone diseases of the musculoskeletal system, IDIVAL; and Department of Rheumatology, Hospital Universitario Marqués de Valdecilla, Santander, Spain, 2Research group on genetic epidemiology and atherosclerosis in systemic diseases and in metabolic bone diseases of the musculoskeletal system, IDIVAL, Santander, Spain, 3Research group on genetic epidemiology and atherosclerosis in systemic diseases and in metabolic bone diseases of the musculoskeletal system, IDIVAL; and Department of Pneumology, Hospital Universitario Marqués de Valdecilla, Santander, Spain, 4Hospital Universitario Marques de Valdecilla, Santander, Cantabria, Spain

    Background/Purpose: The presence of interstitial lung disease (ILD) in patients with autoimmune diseases (AD)s influences significantly on their morbidity and mortality [1]. Different treatment strategies…
  • Abstract Number: 1439 • ACR Convergence 2020

    Proteinase 3-Reactive B Cell Pool Restructuring After Rituximab and Risk of Relapse in Severe PR3-ANCA-Associated Vasculitis

    Alvise Berti1, Sophie Hillion2, Marta Casal Moura1, Amber Hummel1, Eva Carmona1, Tobias Peikert1, Carol Langford3, Peter A. Merkel4, Paul Monach5, Philip Seo6, Robert Spiera7, Eugene St Clair8, Fernando C. Fervenza1, Kristina Harris9, John H. Stone10, Jacques-Olivier Pers11, Ulrich Specks1 and Divi Cornec12, 1Mayo Clinic, Rochester, MN, 2Brest University, Brest, Bretagne, France, 3Cleveland Clinic, Moreland Hills, OH, 4Division of Rheumatology University of Pennsylvania, Philadelphia, PA, 5Brigham and Women's, Boston, 6Johns Hopkins University, Baltimore, MD, 7Division of Rheumatology, Hospital for Special Surgery, New York, New York, USA, New York, NY, 8Duke University, Durham, NC, 9Immune Tolerance Network, Bethesda, MD, 10Massachusetts General Hospital Rheumatology Unit, Harvard Medical School, Boston, MA, 11University of Brest, Brest, France, 12Rheumatology Department, Brest University Hospital, Brest, France

    Background/Purpose: In ANCA-associated vasculitis (AAV) B cells play a central pathogenic role and are instrumental for the production of ANCA, which are thought to mediate…
  • Abstract Number: 1441 • ACR Convergence 2020

    Effects of Belimumab on Renal Outcomes, Overall SLE Control and Biomarkers: Findings from a Phase 3, Randomized, Placebo-controlled 104-week Study in Patients with Active Lupus Nephritis

    Richard Furie1, Brad Rovin2, Frédéric Houssiau3, Gabriel Contreras4, Ana Malvar5, Amit Saxena6, Xueqing Yu7, Y K Onno Teng8, Pieter van Paassen9, Ellen M Ginzler10, Diane Kamen11, Mary Oldham12, Damon Bass13, Andre van Maurik14, Mary Beth Welch13, Yulia Green15, Beulah Ji15, Christi Kleoudis16 and David Roth17, 1Northwell Health, Great Neck, NY, 2The Ohio State University, Columbus, 3Cliniques Universitaires Saint-Luc, Brussels, Belgium, 4University of Miami Miller School of Medicine, Miami, 5Organizacion Medica de Investigacion, Buenos Aires, Argentina, 6NYU School of Medicine, New York, 7Guangdong Provincial People’s Hospital and Guangdong Academy of Medical Sciences, Guangzhou, China (People's Republic), 8Leiden University Medical Center, Leiden, Netherlands, 9Maastricht University, Academisch Ziekenhuis Maastricht, Maastricht, Netherlands, 10SUNY Downstate Health Sciences University, Brooklyn, 11Medical University of South Carolina, Charleston, SC, 12GlaxoSmithKline, Stevenage, United Kingdom, 13GlaxoSmithKline, Research Triangle Park, 14GlaxoSmithKline, Stevenage, 15GlaxoSmithKline, Uxbridge, 16Parexel (*At the time of study), Durham, 17GlaxoSmithKline, Collegeville

    Background/Purpose: Belimumab (BEL) has demonstrated efficacy in systemic lupus erythematosus (SLE) in 4 positive pivotal trials. This study assessed the efficacy and safety of intravenous…
  • Abstract Number: 1452 • ACR Convergence 2020

    Transcriptomic Meta-analysis Reveals a Core Transcriptional Program in Murine B Cell Anergy and Implicates Immunometabolic Regulation as a Central Pathway in Maintaining Non-responsiveness of Autoreactive B-cells in Both Mouse and Man

    Isaac Harley1, Bergren Crute2, Andrew Getahun2 and John Cambier3, 1University of Colorado Anschutz Medical Campus, Aurora, CO, 2University of Colorado – Anschutz Medical Campus, Aurora, 3Univ, Aurora

    Background/Purpose: The mechanisms self-tolerance loss that lead to autoantibody-mediated autoimmune disease remain underdefined. The rapid reversibility of peripheral B-cell tolerance in murine models suggests that…
  • Abstract Number: 1578 • ACR Convergence 2020

    Rituximab Hypersensitivity in Rheumatic and Inflammatory Diseases: Role of Skin Testing

    Sravani Penumarty1, Javier Quintero Betancourt2, Eugenio Capitle2 and Reena Khianey2, 1Rutgers, Eastvale, CA, 2Rutgers, Newark, NJ

    Background/Purpose: Infusion-related reactions have been reported with rituximab, a monoclonal antibody targeting the CD20 antigen on B cells, and may result in discontinuation of the…
  • « Previous Page
  • 1
  • …
  • 9
  • 10
  • 11
  • 12
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology